NCT04270526View on ClinicalTrials.gov

Minimizing Pain During Office Intradetrussor Botox Injection

PHASE4CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

August 15, 2020

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Overactive BladderOveractive DetrusorOveractive Bladder SyndromeOveractivity; BehaviorUrge Incontinence
Interventions
DRUG

Bicarbonate protocol

Intradetrussor treatment with 50 mL 1% lidocaine + 45ml of 0.9% normal saline + 5 mL 8.4% sodium bicarbonate

DRUG

Standard protocol

Intradetrussor treatment with 50 mL 1% lidocaine + 50ml of 0.9% normal saline

Trial Locations (1)

02138

Boston Urogynecology Associates, Cambridge

All Listed Sponsors
lead

Boston Urogynecology Associates

OTHER

NCT04270526 - Minimizing Pain During Office Intradetrussor Botox Injection | Biotech Hunter | Biotech Hunter